Evaluation the effect of 50 and 100 mg doses of Cuminum cyminum essential oil on glycemic indices, insulin resistance and serum inflammatory factors on patients with diabetes type II: A double-blind randomized placebo-controlled clinical trial

Aim: The purpose of this study was to evaluate the effect of 50 and 100 mg doses of green cumin
essential oil on glycemic and inflammatory indices in patients with diabetes type II.
Method: In this randomized double-blind placebo-controlled clinical trial, subjects were divided into
three groups after selecting them randomly according to the inclusion criteria: 1 e Cuminum cyminum
capsule (100 mg/day,n ¼ 33), 2 e C. cyminum capsule (50 mg/day, n ¼ 33), and 3 e placebo (n ¼ 33).
Before and after 8 weeks of intervention, a blood sample was taken.
Findings: The findings demonstrated that the mean of the FBS, glycosylated hemoglobin (HgA1c) and the
serum levels of insulin were significantly decreased and insulin sensitivity (HOMA-IR) was significantly
increased in the groups receiving the 100 mg supplement (P < 0.001) and 50 mg supplement, but these
indices were increased in the placebo group. The mean serum levels of TNF-a and hsCRP were
significantly decreased, and serum levels of adiponectin was significantly increased at the end of the
study in the groups receiving 100 mg (P < 0.001) and 50 mg (P ¼ 0.008) supplement as well as in the
group who received the placebo. There were no significant change in HOMA-B and QUICKI as insulin
resistance parameters.
Discussion and conclusion: Administering C. cyminum supplement in patients with diabetes type II may
decrease the serum levels of insulin, FBS, and glycosylated hemoglobin and also the inflammatory indices
of TNF-a and hsCRP and increased the serum levels of adiponectin. In addition it may control the
complications of diabetes type II in these patients.
Copyright